Into the valley of death: Research to innovation

J Hudson, H F Khazragui

Research output: Contribution to journalArticle

  • 16 Citations

Abstract

The phase between research and successful innovation is known as the Valley of Death. The pharma industry and academia are increasingly working together, often encouraged by governments, as they seek to successfully navigate the Valley and bring research to the market. This is consistent with newer models of innovation policy which stress interaction between the different agents across the innovation process. We examine this interaction, in part through several academic research case studies. They suggest that co-operation has been focused on the research stages of innovation and that academia’s return on its IPR is relatively small. Countries are also beginning to use research as a tool of industrial economic policy.
LanguageEnglish
Pages610-613
Number of pages4
JournalDrug Discovery Today
Volume18
Issue number13-14
Early online date9 Feb 2013
DOIs
StatusPublished - Jul 2013

Fingerprint

Research
Marketing
Industry
Economics

Cite this

Into the valley of death : Research to innovation. / Hudson, J; Khazragui, H F.

In: Drug Discovery Today, Vol. 18, No. 13-14, 07.2013, p. 610-613.

Research output: Contribution to journalArticle

Hudson, J & Khazragui, HF 2013, 'Into the valley of death: Research to innovation' Drug Discovery Today, vol. 18, no. 13-14, pp. 610-613. DOI: 10.1016/j.drudis.2013.01.012
Hudson J, Khazragui HF. Into the valley of death: Research to innovation. Drug Discovery Today. 2013 Jul;18(13-14):610-613. Available from, DOI: 10.1016/j.drudis.2013.01.012
Hudson, J ; Khazragui, H F. / Into the valley of death : Research to innovation. In: Drug Discovery Today. 2013 ; Vol. 18, No. 13-14. pp. 610-613
@article{954addc069684dcdafd25e7d3b8f1aba,
title = "Into the valley of death: Research to innovation",
abstract = "The phase between research and successful innovation is known as the Valley of Death. The pharma industry and academia are increasingly working together, often encouraged by governments, as they seek to successfully navigate the Valley and bring research to the market. This is consistent with newer models of innovation policy which stress interaction between the different agents across the innovation process. We examine this interaction, in part through several academic research case studies. They suggest that co-operation has been focused on the research stages of innovation and that academia’s return on its IPR is relatively small. Countries are also beginning to use research as a tool of industrial economic policy.",
author = "J Hudson and Khazragui, {H F}",
year = "2013",
month = "7",
doi = "10.1016/j.drudis.2013.01.012",
language = "English",
volume = "18",
pages = "610--613",
journal = "Drug Discovery Today",
issn = "1359-6446",
publisher = "Elsevier",
number = "13-14",

}

TY - JOUR

T1 - Into the valley of death

T2 - Drug Discovery Today

AU - Hudson,J

AU - Khazragui,H F

PY - 2013/7

Y1 - 2013/7

N2 - The phase between research and successful innovation is known as the Valley of Death. The pharma industry and academia are increasingly working together, often encouraged by governments, as they seek to successfully navigate the Valley and bring research to the market. This is consistent with newer models of innovation policy which stress interaction between the different agents across the innovation process. We examine this interaction, in part through several academic research case studies. They suggest that co-operation has been focused on the research stages of innovation and that academia’s return on its IPR is relatively small. Countries are also beginning to use research as a tool of industrial economic policy.

AB - The phase between research and successful innovation is known as the Valley of Death. The pharma industry and academia are increasingly working together, often encouraged by governments, as they seek to successfully navigate the Valley and bring research to the market. This is consistent with newer models of innovation policy which stress interaction between the different agents across the innovation process. We examine this interaction, in part through several academic research case studies. They suggest that co-operation has been focused on the research stages of innovation and that academia’s return on its IPR is relatively small. Countries are also beginning to use research as a tool of industrial economic policy.

UR - http://www.scopus.com/inward/record.url?scp=84879957118&partnerID=8YFLogxK

UR - http://dx.doi.org/10.1016/j.drudis.2013.01.012

U2 - 10.1016/j.drudis.2013.01.012

DO - 10.1016/j.drudis.2013.01.012

M3 - Article

VL - 18

SP - 610

EP - 613

JO - Drug Discovery Today

JF - Drug Discovery Today

SN - 1359-6446

IS - 13-14

ER -